Emily Heather, PA
Medical · Pocatello, IDNPI 1780314922
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,978 and has fallen 92.4% since, to $151 in 2025. Among medical clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$365
- Amgen$364
- Astellas Pharma US Inc$303
- Pfizer$255
- GSK$227
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$207
- plus $2K from 20 others
What the payments were for
- Food & beverage$3,484100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $365 |
| Amgen | 13 | $364 |
| Astellas Pharma US Inc | 10 | $303 |
| Pfizer | 12 | $255 |
| GSK | 13 | $227 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $207 |
| Lilly USA, LLC | 12 | $205 |
| Novo Nordisk | 10 | $186 |
| Dexcom, Inc. | 2 | $157 |
| Novartis | 6 | $157 |
| Madrigal Pharmaceuticals | 1 | $135 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $127 |
| AstraZeneca | 7 | $125 |
| Exact Sciences | 5 | $122 |
| Johnson & Johnson | 7 | $121 |
| Idorsia Pharmaceuticals US Inc | 5 | $77 |
| Amneal Pharmaceuticals LLC | 4 | $67 |
| Boehringer Ingelheim | 3 | $63 |
| Bayer | 3 | $54 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Merck | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Cequr Corporation | 1 | $22 |
| Alvogen Inc | 1 | $20 |
| Grifols USA, LLC | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$135
- DEXCOM G7 GSS (161)$122
- EVENITY$120
How this compares
$3,484 in reported general payments places this provider in the 90th percentile of 265 medical providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 22 | $36,240 |
| EliquisApixaban | 21 | $33,431 |
| OzempicSemaglutide | 24 | $31,587 |
| TrulicityDulaglutide | 17 | $23,227 |
| ProliaDenosumab | 13 | $22,422 |
| RexultiBrexpiprazole | 13 | $19,618 |
| XareltoRivaroxaban | 15 | $13,690 |
| MounjaroTirzepatide | 11 | $13,160 |
| Repatha SureclickEvolocumab | 11 | $10,781 |
| Valsartan | 57 | $2,085 |
| Levothyroxine Sodium | 165 | $1,645 |
| SynthroidLevothyroxine Sodium | 18 | $1,521 |
| Rosuvastatin Calcium | 121 | $1,189 |
| Atorvastatin Calcium | 137 | $1,114 |
| Gabapentin | 47 | $865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $205 | $36,38828 claims |
| Boehringer IngelheimJardiance | $63 | $36,24022 claims |
| PfizerEliquis | $255 | $33,43121 claims |
| Novo NordiskOzempic | $186 | $31,58724 claims |
| AmgenProlia | $364 | $22,42213 claims |
| Johnson & JohnsonXarelto | $121 | $13,69015 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $25 | $2,08557 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $67 | $1,645165 claims |
| AbbVieSynthroid | $365 | $1,52118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 medical providers in Idaho.
Other medical in Pocatello
- Tyler HepworthPocatello$7K
- Cameron NelsonPocatello$3K
- Kebai BillsPocatello$2K
- Brett ZundelTerreton$71K
- Jessica BishopBoise$60K
- Kyle GeorgeMeridian$19K
- Jed BartschiIdaho Falls$11K
- Dallin GamblesRexburg$10K
- Cali BradberryBoise$9K
- Weldon RichardsonIdaho Falls$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.